###begin article-title 0
###xml 110 115 <span type="species:ncbi:9606">human</span>
Induction of beta defensin 2 by NTHi requires TLR2 mediated MyD88 and IRAK-TRAF6-p38MAPK signaling pathway in human middle ear epithelial cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 276 281 <span type="species:ncbi:9606">human</span>
All mucosal epithelia, including those of the tubotympanium, are secreting a variety of antimicrobial innate immune molecules (AIIMs). In our previous study, we showed the bactericidal/bacteriostatic functions of AIIMs against various otitis media pathogens. Among the AIIMs, human beta-defensin 2 is the most potent molecule and is inducible by exposure to inflammatory stimuli such as bacterial components or proinflammatory cytokines. Even though the beta-defensin 2 is an important AIIM, the induction mechanism of this molecule has not been clearly established. We believe that this report is the first attempt to elucidate NTHi induced beta-defensin expression in airway mucosa, which includes the middle ear.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 414 415 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 356 361 <span type="species:ncbi:9606">human</span>
Monoclonal antibody blocking method was employed in monitoring the TLR-dependent NTHi response. Two gene knock down methods - dominant negative (DN) plasmid and small interfering RNA (siRNA) - were employed to detect and confirm the involvement of several key genes in the signaling cascade resulting from the NTHi stimulated beta-defensin 2 expression in human middle ear epithelial cell (HMEEC-1). The student's t-test was used for the statistical analysis of the data.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
The experimental results showed that the major NTHi-specific receptor in HMEEC-1 is the Toll-like receptor 2 (TLR2). Furthermore, recognition of NTHi component(s)/ligand(s) by TLR2, activated the Toll/IL-1 receptor (TIR)-MyD88-IRAK1-TRAF6-MKK3/6-p38 MAPK signal transduction pathway, ultimately leading to the induction of beta-defensin 2.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
This study found that the induction of beta-defensin 2 is highest in whole cell lysate (WCL) preparations of NTHi, suggesting that the ligand(s) responsible for this up-regulation may be soluble macromolecule(s). We also found that this induction takes place through the TLR2 dependent MyD88-IRAK1-TRAF6-p38 MAPK pathway, with the primary response occurring within the first hour of stimulation. In combination with our previous studies showing that IL-1alpha-induced beta-defensin 2 expression takes place through a MyD88-independent Raf-MEK1/2-ERK MAPK pathway, we found that both signaling cascades act synergistically to up-regulate beta-defensin 2 levels. We propose that this confers an essential evolutionary advantage to the cells in coping with infections and may serve to amplify the innate immune response through paracrine signaling.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 480 503 480 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae </italic>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 641 642 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 892 893 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 894 895 894 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1015 1016 1015 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1141 1142 1141 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 331 339 <span type="species:ncbi:9606">children</span>
###xml 480 502 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 504 508 <span type="species:ncbi:727">NTHi</span>
The respiratory mucosal epithelia, including the middle ear mucosa, are directly exposed to the environment and serve as an effective first line of defense against a variety of potentially pathogenic microorganisms. Second only to the common cold, otitis media (OM) is the most prevalent mucosal infectious disease affecting young children. OM results in 31 million annual visits to physicians' offices and is estimated to have a yearly cost exceeding $5 billion USD. Nontypeable Haemophilus influenzae (NTHi) [1,2] is one of the major OM pathogens and is also a causing agent for sinusitis and chronic obstructive pulmonary disease (COPD) [3]. In the past three decades, there has been a dramatic worldwide increase in antibiotic resistance in respiratory pathogens. There is, thus, an urgent need to develop new and innovative, non-antibiotic approaches to prevent and manage this disease [4,5]. The pathogenesis of OM is multi-factorial and it is believed that the antimicrobial innate immune molecules (AIIMs) [6-11] as well as pathogen recognition receptors such as the toll-like receptors (TLR) are playing roles in OM susceptibility [3,12,13].
###end p 11
###begin p 12
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 357 359 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 360 362 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 519 521 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 522 524 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 624 626 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 627 629 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 734 736 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 737 739 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 740 742 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 968 970 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 971 973 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1108 1110 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1323 1325 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1472 1474 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1475 1477 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1513 1521 1491 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1854 1856 1832 1834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1857 1859 1835 1837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1860 1862 1838 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1009 1014 <span type="species:ncbi:9606">human</span>
###xml 1102 1106 <span type="species:ncbi:727">NTHi</span>
###xml 1218 1223 <span type="species:ncbi:9606">human</span>
###xml 1483 1488 <span type="species:ncbi:9606">human</span>
###xml 1513 1520 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Innate immune molecules such as lysozyme, lactoferrin, PLUNC (palate, lung and nasal epithelium clone) and defensins are produced by the mucosal epithelial cells and provide the host with continuous innate immunity against a variety of invading pathogens [14,15]. Among the AIIMs, the beta-defensin family is one of the most potent innate immune molecules [16-18]. Some of the major roles defensins play in host defense are direct antimicrobial activity, facilitation and amplification of innate and adaptive immunity [19-22]. To date, multiple beta-defensin genes from epithelial and epididymal cells have been identified [23-25]. Among them, four of epithelial beta-defensins (HBD 1-4) have been characterized at the peptide level [23,24,26]. beta-defensin 1 is expressed constitutively by a variety of cell types, while beta-defensin 2 expression is highly up-regulated by exposure to inflammatory stimuli such as bacterial components or proinflammatory cytokines [20,23]. We have recently shown that both human beta-defensin 1 and 2 (HBD-1 and -2) have bactericidal/bacteriostatic activity against NTHi [14]. Moreover, in a previous study, we demonstrated that IL-1alpha up-regulates the transcription of HBD-2 in human middle ear epithelial cells (HMEEC-1), through the Src dependent Raf-MEK1/2-ERK signaling pathway [27]. However, despite this common generality, the degree of HBD-2 induction was variable in different cell types in response to inflammatory signal [20,28]. In human skin keratinocytes, the E. coli LPS is a weak inducer of HBD-2 signaling, but the induction is greatly increased when monocyte-derived cells were used as intermediaries between LPS and the epidermal keratinocytes. This may be due to the facts that the amplified epidermal response to LPS is mediated through the IL-1 pathway which is the dominant inducer of HBD-2 [20,29,30]. It is possible that HBD-2 and IL-1 signal amplification is mediated through TLRs.
###end p 12
###begin p 13
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1297 1299 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1300 1302 1300 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1447 1449 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1722 1724 1722 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 2010 2012 2010 2012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1512 1516 <span type="species:ncbi:727">NTHi</span>
The innate immune system has been known to utilize the Toll-like receptors (TLRs) for recognition of pathogen-associated molecular patterns (PAMPs), thus activating the MAPK or the NF-kB-dependent cell signaling cascades, resulting in a rapid, full-blown proinflammatory response [19]. TLR proteins are a family of type I trans-membrane receptors consisting of an NH2-terminal extracellular leucine-rich repeat domain (LRR) and a COOH-terminal intracellular Toll/IL-1 receptor (TIR) homology domain [31,32]. The intracellular TIR domain is a region of 150 amino acids with three highly conserved regions [33]. This TIR domain plays an important role in mediating protein-protein interactions between TLR proteins and their downstream signal transduction components such as the MyD88 protein [13]. The MyD88 recruited via its TIR domain to the TLR receptor promotes association with the interleukin-1 receptor-associated kinase 1 (IRAK1) [13,34]. The phosphorylation of IRAK1 results in its dissociation from the complex and its interaction with the tumor necrosis factor receptor-associated factor 6 (TRAF6) [13,34]. Activation of the TLR2-MyD88-IRAK1-TRAF6 can lead to the activation of many downstream signaling pathways, including members of the mitogen-activated protein kinase (MAPK) family [19,35]. At least three MAPK families have been identified to date: extracellular signal-regulated kinase (ERK), c-Jun kinase (JNK/SAPK) and p38 MAPK [19]. Among the three possible MAPK pathways, we hypothesize that NTHi WCL-induced HBD-2 up-regulation in HMEEC-1 takes place through the p38 MAPK cascade. Furthermore, TIR-like motifs in receptors from various plant species have also been shown to confer disease resistance [33], indicating a evolutionarily conserved functional role for this domain across species. Even though the IL-1 receptor and TLR are composed of different extracellular receptors, similarities between their intracellular TIR domains leads them to exhibit similar immunological responses [32]. This fact leads us to hypothesize that the possible interaction of the two domains is important to the synergistic induction of HBD-2.
###end p 13
###begin p 14
###xml 282 284 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 209 213 <span type="species:ncbi:727">NTHi</span>
In this study we show that NTHi12 induced HBD-2 up-regulation mainly takes place through the TLR2-MyD88-IRAK1-TRAF6-MKK3/6-p38 MAPK pathway. This result may also explain the significant synergistic effects of NTHi and IL-1alpha co-stimulation in expression and regulation of HBD-2 [30].
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Bacterial culture and preparation of whole cell lysate
###end title 16
###begin p 17
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 396 397 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1233 1235 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1236 1238 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 4 8 <span type="species:ncbi:727">NTHi</span>
###xml 189 193 <span type="species:ncbi:727">NTHi</span>
###xml 1044 1048 <span type="species:ncbi:727">NTHi</span>
###xml 1079 1083 <span type="species:ncbi:727">NTHi</span>
###xml 1093 1097 <span type="species:ncbi:727">NTHi</span>
The NTHi strain 12 used in this study is a clinical isolate and it has been well documented [14,36,37]. The preparation procedure was described in a previous paper [14]. Briefly, stocks of NTHi 12 (obtained from Dr. Steve Barenkamp, St. Louis University, School of Medicine) were maintained at -80degreesC. The bacteria were plated on chocolate agar and incubated overnight at 37degreesC in 5% CO2. A single colony was used to inoculate 10 ml of brain heart infusion (BHI, Becton Dickinson, Cockeysville, MD), supplemented with hemin (10 mug/ml, Sigma, St. Louis, MO) and nicotinamide adenine dinucleotide (NAD10 mug/ml, Sigma, St. Louis, MO), and allowed to grow overnight. The bacteria were collected at 5,000 x g for 10 min and washed three times in phosphate buffered saline (PBS). After sonication, the lysate was cleared by centrifugation at 10,000 x g for 10 min. The cleared whole cell lysate (WCL) was collected and stored at -80degreesC and the pellet (P) was resuspended in PBS. To compare variations of HBD-2 induction by different NTHi strains, we prepared WCL from NTHi 2019 and NTHi 9274 (kind gifts from Dr. Michael Apicella, The university of Iowa, Department of Microbiology) using the same method described above [38-40].
###end p 17
###begin title 18
Mammalian epithelial cell culture
###end title 18
###begin p 19
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 439 445 <span type="species:ncbi:9913">bovine</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
###xml 868 874 <span type="species:ncbi:9913">bovine</span>
The human middle ear epithelial cell line (HMEEC-1) used in this study was immortalized with the E6/E7 genes of human papilloma virus type 16 and has been used in number of cell signaling studies [27,30,41,42]. HMEEC-1 cells were maintained in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Inc, Gaithersburg, MD) and Bronchial Epithelial Basal Medium (BEBM) (Clonetics, Walkersville, MD) supplemented with bovine pituitary extract (52 mug/ml), hydrocortisone (0.5 mug/ml), hEGF (0.5 ng/ml), epinephrine 0.5 (mug/ml), transferrin (10 mug/ml), insulin (5 mug/ml), triiodothyronine (6.5 ng/ml), retinoic acid (0.1 ng/ml), gentamycin (50 mug/ml) and amphotericin-B (50 ng/ml). All cells were cultured in a humidified atmosphere of 5% CO2 and 95% air. A549 (human lung carcinoma) cell lines were cultured in DMEM supplemented with 5% fetal bovine serum (Life Technologies, Inc., Gaithersburg, MD).
###end p 19
###begin title 20
Blocking TLR2/TLR4 with monoclonal-Antibody
###end title 20
###begin p 21
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 217 221 <span type="species:ncbi:727">NTHi</span>
HMEEC-1 cells were cultured to 80% confluence and treated with 10 mug/ml of human TLR2 or TLR4 blocking antibodies (eBioscience, San Diego, CA) for 30 minutes at room temperature followed by stimulation with 5 mug/ml NTHi WCL for 4 hours. Isogenic antibody (IgG2a, k) was used as the control. All experiments were done in triplicates.
###end p 21
###begin title 22
Plasmid transfection and chemical inhibitors
###end title 22
###begin p 23
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 574 578 <span type="species:ncbi:727">NTHi</span>
###xml 1026 1030 <span type="species:ncbi:727">NTHi</span>
HMEEC-1 cells were cultured in 12 well plates for 24 hours and then transiently transfected with appropriate dominant-negative mutant (DN) plasmids - hTLR2 DN, MyD88 DN, and TRAF6 DN (described previously [43,44]) and hTLR4 DN and IRAK1 DN (kindly provided by Dr. Jian-Dong Li) and pcDNA3.1 (Invitrogen, Carlsbad, CA) served as the control. All transient transfections were carried out in triplicate using a concentration of 1 mug/ml of plasmid and TransIT-LT1 reagent (Mirus, Madison, WI) following the manufacturer's instructions. 42 hours after transfection, 5 mug/ml of NTHi WCL was added to the cells for 4 hours. In all DN transfection experiments, a background vector was used as a negative control. For chemical signal blocking study, the HMEEC-1 cells were cultured for 2 days to 80% confluence. The cells were grown overnight in basic medium without supplement then pre-treated with 5 muM chemical inhibitors, SB203580, PD98059, U0126 (Calbiochem Inc., La Jolla, CA) or vehicle for 1 hour followed by treatment with NTHi WCL for 4 hours.
###end p 23
###begin title 24
Animal studies
###end title 24
###begin p 25
###xml 57 65 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 591 593 588 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 76 80 <span type="species:ncbi:727">NTHi</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:727">NTHi</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 1005 1009 <span type="species:ncbi:727">NTHi</span>
###xml 1018 1022 <span type="species:ncbi:10090">mice</span>
10 week-old C57BL/6 male mice were used for studying the in vivo kinetic of NTHi induced mBD-2 expression. All aspects of animal handling were performed according to approved HEI IACUC protocols. The mice were transtympanically inoculated with 10 mul of the NTHi WCL after being anesthetized with Ketamine (5 mg/100 g). 1x PBS solution (10 mul) was used as the negative control. At 0, 6, 9, 12 and 24 hours post-inoculation, the middle ear mucosal RNA of three mice were harvested by irrigation of the bulla with three, 3.5 mul volume of Trizol (Invitrogen). The mice were sacrificed with CO2 and then decapitated. A small incision (1 cm) was made in the retroauricular area and the cortical bone of the bulla was exposed after dissection. A 2 mm x 2 mm sized hole was made using a sharp scalpel followed by irrigation of the bulla with Trizol. The total Trizol volume was then increased to 200 mul and RNA was precipitated using the manufacturer's instructions. The middle ear mucosa was inflamed in all NTHi-treated mice, but effusion was not seen in all groups. No sepsis or death occurred as a result of the experimental treatment.
###end p 25
###begin p 26
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 117 121 <span type="species:ncbi:727">NTHi</span>
To compare mouse beta-defensin 2 (mBD-2) expression in TLR2 KO and wild type animals, the right ear was treated with NTHi WCL while the left ear served as a PBS treated control. The middle ear mucosal RNA was collected at 4 hours post-inoculation and analyzed by real-time quantitative PCR.
###end p 26
###begin title 27
RNA extraction and real-time quantitative RT-PCR analysis
###end title 27
###begin p 28
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 496 501 <span type="species:ncbi:10090">mouse</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 597 602 <span type="species:ncbi:9606">human</span>
###xml 674 679 <span type="species:ncbi:9606">human</span>
###xml 749 754 <span type="species:ncbi:10090">mouse</span>
RNA from cell lines or middle ear mucosa was extracted using Trizol (Invitrogen, Carlsbad, CA) and cDNA was synthesized using SuperScript II RNase H- reverse transcriptase according to the manufacturer's protocol (Life Technologies, Inc, Gaithersburg, MD). Applied Biosystems' Assays-on-Demand primer and probe sets were then used to perform real-time quantitative PCR on each sample. In each case, the Cyclophilin gene served as the internal standard. The assays used were as follows: 1) Defb2 (mouse beta-defensin 2), ABI assay number Mm00657074_m1(NM_010030.1); 2) DEFB4 (human beta-defensin 2/human beta-defensin 4), ABI assay number Hs00823638_m1 (NM_004942); 3) PPID (human cyclophilin D), ABI assay number Hs00234593_m1 (NM_005038); 4) Ppid (mouse cyclophilin D) ABI assay number Mm00835365_g1 (NM_026352). The relative quantity (CT treshhold method) of beta-defensin 2 mRNA was quantitated.
###end p 28
###begin title 29
Western blot analysis and kinase assays
###end title 29
###begin p 30
###xml 957 968 <span type="species:ncbi:3704">horseradish</span>
Cells were lysed using a buffer solution containing 25 mM TrisCl, 1 mM EDTA, 5 mM MgCl 2, 1 mM DTT, 100 mM NaCl, 10% glycerol, 1% Triton x-100, 1 mM PMSF, and 5 mug/ml each of leupeptin, aprotinin, and pepstatin. The homogenate was centrifuged at 13,000 rpm for 10 min and the supernatant collected. Protein concentration was measured with the BCA protein assay kit (Bio-Rad, Inc., Richmond, CA). Cell lysates containing 50 mug of protein were boiled for 5 min in reducing SDS-PAGE sample buffer (0.125 Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 10% beta-mercaptoethanol, and 0.2% bromophenol), and run on SDS-PAGE. The bands were transferred to a 0.2-mum pore nitrocellulose membrane (Whatman, Sanford, ME) in 20% methanol, 25 mM Tris, and 192 mM glycine, pH 8.3. The membrane was blocked with 5% milk, followed by exposure to the primary antibody (p38 alpha/beta and phospho-p38 alpha/beta, Cell Signaling Inc., Beverly, MA). A secondary antibody coupled to horseradish peroxidase (1:10,000; Amersham Biosciences) was used to bind to the primary antibody and be detected using enhanced chemiluminescence (NEN Life Science Products).
###end p 30
###begin title 31
siRNA Transfection and ELISA
###end title 31
###begin p 32
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NeoFX </italic>
###xml 699 703 <span type="species:ncbi:727">NTHi</span>
Small interfering RNA (siRNA) was used for transient gene knock-down studies. All transient transfections were carried out in triplicate using NeoFX reagent (Ambion, Austin, TX) to final concentration of 10 nM following the manufacturer's instructions. The siRNAs used were as follows: 1) TLR2, siRNA #111285; 2) MyD88, siRNA #11601; 3) IRAK1, siRNA #138; 4) TRAF6, siRNA #107476; 5) MKK3, siRNA #1609; 6) MKK6, siRNA #1321; 7) p38, siRNA #1312 and siRNA #1 for the negative control. After 20 hours, the transfected cells were grown in fresh medium and cultured for another 48 hrs. The efficiency of gene knock down was evaluated by either RT-PCR or quantitative PCR. The cells were then exposed to NTHi WCL (5 mug/ml) for either 4 hours (gene expression study) or 24 hours (measuring protein). In the latter case, the culture supernatant was harvested and measured by ELISA (Phoenix Pharmaceuticals, Inc., Belmont, CA). For gene expression analysis, total RNA was isolated from the cells and used for real-time quantitative PCR.
###end p 32
###begin title 33
Statistics
###end title 33
###begin p 34
All experiments were carried out in triplicate. Results are expressed as mean +/- standard deviation. The student's t-test was used to measure significance.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 73 82 70 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 86 93 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 4 <span type="species:ncbi:727">NTHi</span>
NTHi up-regulates beta-defensin 2 expression in mucosal epithelial cells in vitro and in vivo
###end title 36
###begin title 37
In vitro
###end title 37
###begin p 38
###xml 63 71 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1034 1036 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 20 24 <span type="species:ncbi:727">NTHi</span>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 147 151 <span type="species:ncbi:727">NTHi</span>
###xml 172 176 <span type="species:ncbi:727">NTHi</span>
###xml 287 291 <span type="species:ncbi:727">NTHi</span>
###xml 554 558 <span type="species:ncbi:727">NTHi</span>
###xml 613 617 <span type="species:ncbi:727">NTHi</span>
###xml 740 744 <span type="species:ncbi:727">NTHi</span>
###xml 881 885 <span type="species:ncbi:727">NTHi</span>
###xml 921 926 <span type="species:ncbi:9606">human</span>
To find out whether NTHi can increase expression of HBD-2 mRNA in vitro, we first treated human middle ear epithelial cells (HMEEC-1) with various NTHi preparations - live NTHi, WCL, pellet, and lipooligosaccharide (LOS). The greatest induction of HBD-2 expression was observed with the NTHi WCL preparation, which suggests that the ligand(s) may be a soluble protein. Even though the other preparations also induced HBD-2, the levels were negligible compared to that of WCL (Fig 1A). Similar experiments using WCL preparations from different strains of NTHi showed no significant differences between the various NTHi strains in inducing HBD-2 expression (Fig 1B). Fig 2A shows the kinetics of HBD-2 expression upon exposure to 5 mug/ml of NTHi WCL. As is evident from the figure, the expression peaked at 4 hours post-treatment then gradually waned out. The induction of HBD-2 by NTHi was also observed in A549 cells (a human lung carcinoma cell line), with near-maximal levels of expression occurring at 8 hours post-treatment (Fig 2B).
###end p 38
###begin p 39
###xml 0 133 0 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Induction of &#946;-defensin 2 (HBD-2) in human middle ear epithelial cells (HMEEC-1) using various NTHi preparations or NTHi variants.</bold>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 98 102 <span type="species:ncbi:727">NTHi</span>
###xml 119 123 <span type="species:ncbi:727">NTHi</span>
###xml 193 197 <span type="species:ncbi:727">NTHi</span>
###xml 248 252 <span type="species:ncbi:727">NTHi</span>
###xml 290 294 <span type="species:ncbi:727">NTHi</span>
###xml 416 420 <span type="species:ncbi:727">NTHi</span>
###xml 625 629 <span type="species:ncbi:727">NTHi</span>
Induction of beta-defensin 2 (HBD-2) in human middle ear epithelial cells (HMEEC-1) using various NTHi preparations or NTHi variants. With the exception of lipoolygosaccharide (LOS), all other NTHi preparations were derived from the same colony of NTHi strain 12. The LOS was purified from NTHi 12 and used at a concentration of 500 ng/ml. Live NTHi12 was treated using an multiplicity of infection (MOI) of 100 and NTHi WCL (whole cell lysate) and P (Pellet) were used at a concentration of 5 mug/ml. (A), The WCL treatment induced substantially higher expression of HBD-2 than other preparations. (B), Different strains of NTHi WCL were prepared and treated at the same concentration (5 mug/ml). The induction of HBD-2 mRNA was not significantly different between the tested strains. Values are given as mean +/- standard deviation. N = 3. *: p < 0.05.
###end p 39
###begin p 40
###xml 0 139 0 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NTHi whole cell lysate (WCL) up-regulates &#946;-defensin 2 (HBD-2) gene expression in immortalized human mucosal epithelial cells (HMEEC-1).</bold>
###xml 533 540 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 4 <span type="species:ncbi:727">NTHi</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 140 144 <span type="species:ncbi:727">NTHi</span>
###xml 311 315 <span type="species:ncbi:727">NTHi</span>
###xml 439 443 <span type="species:ncbi:727">NTHi</span>
###xml 462 467 <span type="species:ncbi:10090">mouse</span>
###xml 515 520 <span type="species:ncbi:10090">mouse</span>
###xml 542 546 <span type="species:ncbi:727">NTHi</span>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
NTHi whole cell lysate (WCL) up-regulates beta-defensin 2 (HBD-2) gene expression in immortalized human mucosal epithelial cells (HMEEC-1). NTHi treatment of HMEEC-1 (A) and A549 epithelial cells (B) increased the mRNA levels of beta-defensin 2. The x-axis shows the time during which the cells were exposed to NTHi WCL (5 mug/ml). The y-axis represents the signal derived from quantitative PCR on total RNA extracted from the cells. (C), NTHi also up-regulates mouse beta-defensin 2 (mBD-2) mRNA expression in the mouse middle ear, in vivo. NTHi WCL (10 mul) was transtympanically inoculated into the middle ears of anesthetized C57BL/6J mice. Animals were sacrificed at the indicated time points and total RNA extracted from the middle ear mucosa (n = 3). Values are given as mean +/- standard deviation.
###end p 40
###begin title 41
In vivo
###end title 41
###begin p 42
###xml 98 107 97 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 133 135 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 53 57 <span type="species:ncbi:727">NTHi</span>
Mice middle ear epithelium inoculated with 10 mul of NTHi WCL showed very similar kinetics to the in vitro cell line data above (Fig 2C).
###end p 42
###begin title 43
###xml 68 72 <span type="species:ncbi:727">NTHi</span>
The TLR2-depedent MyD88-IRAK-TRAF6 signaling cascade is involved in NTHi-induced up-regulation of beta-defensin 2 mRNA
###end title 43
###begin title 44
Antibody blocking and knock-out animal experiment
###end title 44
###begin p 45
###xml 406 408 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 745 747 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 755 763 749 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 25 29 <span type="species:ncbi:727">NTHi</span>
###xml 168 172 <span type="species:ncbi:727">NTHi</span>
###xml 382 386 <span type="species:ncbi:727">NTHi</span>
###xml 494 498 <span type="species:ncbi:727">NTHi</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:727">NTHi</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:727">NTHi</span>
Having demonstrated that NTHi can up-regulate beta-defensin 2 mRNA in HMEEC-1, we next sought to identify the cell surface receptor that is responsible for recognizing NTHi ligand(s) and initiating the appropriate signaling cascade. Pre-incubation of HMEEC-1 with a TLR2 specific blocking antibody dramatically reduced the expression of HBD-2 in HMEEC-1 cell culture in response to NTHi WCL treatment (Fig 3A), indicating that TLR2 plays a major role in this pathway. The importance of TLR2 in NTHi WCL-induced beta-defensin 2 production was also tested in gene knock out animals. The induction rate of mBD-2 expression in TLR2 KO mice middle ear epithelial cells in response to NTHi WCL was substantially lower than that of wild type mice (Fig 3B). This in vivo experiment confirmed the critical role of TLR2 in NTHi induced cell signaling that resulted in the production of the highly potent antimicrobial innate immune molecule - beta-defensin 2 - by the middle ear epithelial cells.
###end p 45
###begin p 46
###xml 0 120 0 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The TLR2 blocking antibody inhibition of NTHi induced HBD-2 mRNA expression in HMEEC-1 cells and in TLR2 knock out mice.</bold>
###xml 723 727 715 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 41 45 <span type="species:ncbi:727">NTHi</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 298 302 <span type="species:ncbi:727">NTHi</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 534 538 <span type="species:ncbi:727">NTHi</span>
###xml 624 628 <span type="species:ncbi:727">NTHi</span>
###xml 655 661 <span type="species:ncbi:10090">murine</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">Mice</span>
###xml 780 784 <span type="species:ncbi:727">NTHi</span>
The TLR2 blocking antibody inhibition of NTHi induced HBD-2 mRNA expression in HMEEC-1 cells and in TLR2 knock out mice. (A) Pretreatment of HMEEC-1 with human TLR2 blocking antibody for 30 minutes (10 mug/ml, clone TL2.1, eBioscience) reduced the HBD-2 mRNA expression dramatically in response to NTHi lysate stimulation (5 mug/ml). In contrast, human TLR4 blocking antibody did not show any significant effect suggesting that TLR2 is one of the major signaling receptors for inducing human beta-defensin 2 expression in response to NTHi stimulation in HMEEC-1. The control group was treated with an isogenic antibody. (B) NTHi WCL-induced expression of murine beta-defensin 2 mRNA (mBD-2) in wild type (C57 BL/6) and TLR2-/- mice was compared. Mice were injected with 10 mul of NTHi WCL transtympanically in the left ear. The right ear served as a PBS injected control. Four hours post-injection, the total RNA was harvested and Defb2 expression measured by quantitative PCR (n = 3). Values are given as mean +/- standard deviation. N = 3. *: p < 0.05.
###end p 46
###begin title 47
siRNA
###end title 47
###begin p 48
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 592 594 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 621 623 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 810 812 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1087 1089 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 184 188 <span type="species:ncbi:727">NTHi</span>
###xml 483 487 <span type="species:ncbi:727">NTHi</span>
###xml 846 850 <span type="species:ncbi:727">NTHi</span>
###xml 1052 1056 <span type="species:ncbi:727">NTHi</span>
We also used TLR2 knock-down experiments to assess the involvement of TLR2 in the pathway using small interfering RNA (siRNA) specific for TLR2. As shown in Fig 4A, HBD-2 induction by NTHi was inhibited in the presence of TLR2-specific siRNAs. Furthermore, similar siRNA experiments also revealed the involvements of interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF6) (Fig 4A) as well as MKK3/6 and p38 MAPK (Fig 4B) in NTHi induced beta-defensin expression. The efficiency of gene knock down was confirmed by either RT-PCR (Fig 4C) or quantitative PCR (Fig 4D). The Q-PCR results showed 60-70% reduction of target gene expression in TLR2, IRAK1, MKK6 and p38 siRNA treated HMEEC-1 compared with those of negative control siRNA treated cells (Fig 4D). In the presence of 5 mug/ml of NTHi WCL for 24 hours, beta-defensin 2 production was also inhibited when cells were transfected with TLR2, IRAK1, MKK3 and MKK6 siRNAs, indicating the direct involvement of these proteins in mediating the NTHi-induced HBD-2 expression (Fig 4E).
###end p 48
###begin p 49
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NTHi-induced HBD-2 expression in HMEEC-1 utilizes the TLR2-dependent IRAK-TRAF6-p38MAPK signaling cascade.</bold>
###xml 0 4 <span type="species:ncbi:727">NTHi</span>
###xml 603 607 <span type="species:ncbi:727">NTHi</span>
###xml 661 665 <span type="species:ncbi:727">NTHi</span>
NTHi-induced HBD-2 expression in HMEEC-1 utilizes the TLR2-dependent IRAK-TRAF6-p38MAPK signaling cascade. (A and B) Cells treated with siRNA specific for TLR2, interleukin receptor associated kinase 1 (IRAK1), tumor necrosis factor receptor associated factor 6 (TRAF6), MAP kinase kinase 3 (MKK3), MKK6 and p38 showed significantly lower HBD-2 expression compared to a negative control. (C) The targeted gene knock down using siRNA was confirmed either by RT-PCR or(D) quantitative PCR. (E) Reduced HBD-2 peptide production in the HMEEC-1 cells treated with target specific siRNA, after treatment with NTHi lysate. The siRNA knock down cells were treated with NTHi lysate for 24 hours. The culture supernatant was collected and HBD-2 protein levels were measured by ELISA. The HBD-2 secretion from cells with target gene knock down was substantially lower than in negative siRNA treated controls. In experiments A, B, D and E, values are given as mean +/- standard deviation. N = 3. *: p < 0.05.
###end p 49
###begin title 50
Dominant negative (DN) plasmids
###end title 50
###begin p 51
###xml 353 355 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 412 414 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 415 417 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 583 585 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 837 839 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 296 300 <span type="species:ncbi:727">NTHi</span>
###xml 796 800 <span type="species:ncbi:727">NTHi</span>
To validate the involvement of MyD88, IRAK1, and TRAF6 in the pathway, we over-expressed dominant-negative mutant (DN) plasmids of each gene associated with the pathway. TLR2 DN, but not TLR4 DN, resulted in inhibition of HBD-2 expression, confirming that TLR2 is the main receptor that mediates NTHi signaling through induction of beta-defensin 2 (Fig 5A). The adaptor molecule MyD88 has previously been shown [13,35] to be the first molecule in the signaling cascade, immediately downstream of TLR2. Cells treated with MyD88DN show a substantial reduction in HBD-2 expression (Fig 5A), validating the involvement of this molecule in the pathway. The reduction of HBD-2 expression in IRAK1 and TRAF6 dominant-negative mutants over-expressed cells confirmed the involvement of these genes in the NTHi induced up-regulation of HBD-2 (Fig 5B).
###end p 51
###begin p 52
###xml 0 130 0 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) TLR2 and MyD88 dominant-negative (DN) mutants, but not TLR4 DN mutant, inhibit NTHi-induced up-regulation of HBD-2 expression.</bold>
###xml 83 87 <span type="species:ncbi:727">NTHi</span>
###xml 517 521 <span type="species:ncbi:727">NTHi</span>
###xml 621 625 <span type="species:ncbi:727">NTHi</span>
###xml 706 710 <span type="species:ncbi:727">NTHi</span>
(A) TLR2 and MyD88 dominant-negative (DN) mutants, but not TLR4 DN mutant, inhibit NTHi-induced up-regulation of HBD-2 expression. (B) The MyD88 downstream signaling proteins, IRAK1 and TRAF6 are also involved in this up-regulation. (C) The kinetics of P38 phosphorylation: phosphorylation of p38 MAPK started at 15 minutes post-treatment, peaked at 45 minutes post-treatment and then disappeared after 60 minutes. (D) Inhibition of p38 MAPK by SB203580, a specific inhibitor of p38, abolishes HBD-2 up-regulation by NTHi. Cells were pretreated with 5 muM of SB203580, PD98059, and U0126 for 1 hour and then treated with NTHi WCL (5 mug/ml) for 4 hours. Only SB203580 exhibited inhibitory activity towards NTHi WCL-specific HBD-2 expression. The ERK inhibitors, PD98059 and U0126 showed little or no effect. In experiments A, B and D, values are given as mean +/- standard deviation. N = 3. *: p < 0.05.
###end p 52
###begin title 53
###xml 82 86 <span type="species:ncbi:727">NTHi</span>
The p38 MAP Kinase pathway is involved in the up-regulation of beta-defensin 2 by NTHi
###end title 53
###begin p 54
###xml 16 18 16 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 459 461 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 46 50 <span type="species:ncbi:727">NTHi</span>
As shown in Fig 5C, treatment of HMEEC-1 with NTHi WCL (5 mug/ml) results in the rapid phosphorylation of p38 MAPK protein. The phosphorylation peaked at 45 minutes post-treatment and rapidly disappeared 60 minutes after treatment. Exposure to SB203580, a specific inhibitor of p38 alpha and beta, exhibited an inhibition in beta-defensin 2 expression, while treatment with PD98059 and U0126, both inhibitors of MEK, did not show any significant effects (Fig 5D).
###end p 54
###begin title 55
Discussion
###end title 55
###begin p 56
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1167 1168 1167 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1169 1171 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 222 228 <span type="species:ncbi:9606">humans</span>
###xml 776 783 <span type="species:ncbi:9606">infants</span>
###xml 794 802 <span type="species:ncbi:9606">children</span>
Antimicrobial innate immune molecules produced by the epithelial cells provide the host with a constitutive or immediately inducible defense mechanism against invading pathogens. Under normal conditions, the middle ear of humans and laboratory animals remains sterile, although OM pathogens, which are part of the normal nasopharyngeal flora can reach the middle ear via the Eustachian tube causing infection [45]. Furthermore, non-inflamed tubal and middle ear mucosa have been shown to contain relatively few immunocytes [46,47]. All of these findings suggest that the components of the innate immune system may be important in the defense of the tubotympanum (middle ear and Eustachian tube). Furthermore, due to the premature and under-developed adaptive immune system in infants and young children, the role of AIIMs in protecting against OM pathogens becomes of paramount importance. Park and Lim [10] showed that the lysozyme positive cells in the epithelium and glandular structures of the Eustachian tube of adult and early post-natal animals were similar. Our previous studies also showed synergistic antimicrobial activities of AIIMs against OM pathogens [8,14]. These results lend strong support to the hypothesis that AIIMs protect the tubotypmpanum during the neonatal and early postnatal periods when the adaptive immunity is not yet fully developed.
###end p 56
###begin p 57
###xml 225 226 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 227 229 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 230 232 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 233 235 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 236 238 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 428 430 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 190 194 <span type="species:ncbi:727">NTHi</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
Among the AIIMs, beta-defensin 2 plays a pivotal role against major OM pathogens and previous studies have shown that this molecule is inducible by a variety of agents, including cytokines, NTHi and its components/molecules [8,14,23,27,30]. Furthermore, we have previously shown that this molecule is expressed at high levels in the middle ear mucosa of patients with OM, but it is undetectable in the normal middle ear mucosa [27].
###end p 57
###begin p 58
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 506 508 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 513 515 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 518 520 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 710 712 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 713 715 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 20 24 <span type="species:ncbi:727">NTHi</span>
###xml 541 545 <span type="species:ncbi:727">NTHi</span>
Some LOS mutants of NTHi exhibit reduced virulence and require higher doses in order to induce OM [48]. Mutations in certain bacterial membrane components alter the susceptibility of the mutants towards AIIMs [49,50]. However, these mutations did not significantly affect the inducibility of HBD-2 expression. To date, the exact nature and identity of the beta-defensin 2 inducing molecule(s) remains elusive, but what is known is that it is maximally active and is present in the soluble WCL portion (Fig 1A and 1B) [51]. Currently several NTHi macromolecules have been identified as vaccine candidates, which include adhesins, high molecular weight adhesins, pilus proteins, outer membrane proteins and LOS [52-55]. Identification of induction of the responsible ligand for beta-defensin 2 requires more research.
###end p 58
###begin p 59
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
###xml 580 582 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 924 926 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 15 19 <span type="species:ncbi:727">NTHi</span>
###xml 361 366 <span type="species:ncbi:10090">mouse</span>
###xml 388 392 <span type="species:ncbi:727">NTHi</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
Treatment with NTHi WCL causes a substantial increase in HBD-2 mRNA expression in both HMEEC-1 and A549 cells. However, the kinetics of HBD-2 expression is a little different between the two cell lines (Fig 2A and 2B), which may be the result of the fact that different cells respond differently even to the same bacterial components [20]. In vivo induction of mouse beta defensin-2 with NTHi WCL treated mice middle ear epithelia exhibits a similar trend to that of HMEEC-1; the mRNA level peaked at 6 hour post-inoculation and dropped back down to basal levels by 12 hours (Fig 2C). This rapid increase in mouse beta defensin-2 levels may indicate that the middle ear epithelial cells, but not inflammatory cells, were the sole source of the mouse beta defensin-2 mRNA - beta defensins are mainly produced by epithelial cells since monocytes would not have yet begun infiltrating the middle ear cavity during this period [56].
###end p 59
###begin p 60
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 166 170 <span type="species:ncbi:727">NTHi</span>
###xml 249 253 <span type="species:ncbi:727">NTHi</span>
###xml 506 510 <span type="species:ncbi:727">NTHi</span>
The Toll-like receptors (TLRs) have been shown to be critical for the recognition of bacteria and recent studies have demonstrated that TLR2 and TLR4 are involved in NTHi signaling [3,57]. To test the involvement of either TLR2 or TLR4 in mediating NTHi WCL induced HBD-2 up-regulation, we used blocking antibodies, siRNA, and dominant negative mutants of TLR2 and TLR4 to inhibit the receptors' activities (Figs 3 - 5). All three methods revealed TLR2 as being the primary receptor for the recognition of NTHi WCL component.
###end p 60
###begin p 61
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 170 174 <span type="species:ncbi:727">NTHi</span>
###xml 973 977 <span type="species:ncbi:727">NTHi</span>
Based on these results, we investigated the role and identity of other possible players downstream of the TLR2 pathway that may be involved in HBD-2 up-regulation by the NTHi WCL such as MyD88, which was previously shown to be the first molecule in the signaling cascade immediately downstream of the TLR2 [13] and its associated proteins, interleukin-1 receptor-associated kinase 1 (IRAK1) [13,19] and tumor necrosis factor receptor-associated factor 6 (TRAF6). MyD88 is recruited via its TIR death domain and promotes association and phosphorylation of the IRAK1. The phosphorylation of IRAK1 results in its dissociation from the complex and its interaction with TRAF6. This interaction results in the activation of downstream signaling in the majority of the epithelial cells studied [13,19]. Our results using siRNA (Fig 4A, 4B &4E) and DN plasmids (Fig 5A &5B) indicate that MyD88, IRAK1 & TRAF6 are directly involved in regulating HBD-2 expression in the presence of NTHi WCL.
###end p 61
###begin p 62
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 784 786 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 788 790 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 1053 1055 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1429 1436 1420 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 398 402 <span type="species:ncbi:727">NTHi</span>
###xml 820 824 <span type="species:ncbi:727">NTHi</span>
###xml 1366 1370 <span type="species:ncbi:727">NTHi</span>
###xml 1455 1460 <span type="species:ncbi:10090">mouse</span>
###xml 1493 1497 <span type="species:ncbi:727">NTHi</span>
###xml 1513 1517 <span type="species:ncbi:10090">mice</span>
Activation of the TLR2-MyD88-IRAK1-TRAF6 can lead to the activation of many downstream signaling pathways, including members of the mitogen-activated protein kinase (MAPK) family [19,35]. Previous studies have suggested that the p38 MAPK pathway is involved in HBD-2 induction in other cell systems [20,58,59]. We therefore sought to determine if p38 MAPK can act as a major signaling mediator for NTHi induced beta-defensin 2 expression. Indeed, our results support data from previous work since such up-regulation was greatly inhibited by SB203580, a specific inhibitor of p38 MAPK but not by ERK inhibitors such as PD98059 and U0126. Also we used siRNA gene knock down to confirm the involvement of p38 MAPK and its associated upstream activators - MKK3 and MKK6. The results (Fig 4B &4E) support our hypothesis that NTHi WCL-specific HBD-2 up-regulation in HMEEC-1 takes place through the p38 MAPK cascade. The kinetics of this signaling was very rapid; phosphorylation of p38 MAPK started 15 minutes after stimulation and peaked at 45 minutes (Fig 5C). Near complete dephosphorylation was achieved by 60 minutes post-stimulation. Secretion of the beta-defensin 2 was also reduced in cells treated with siRNAs targeted for down-regulating TLR2, IRAK1, TRAF6, and MKK(3/6) signaling molecules compared to a negative control. The importance of the role of TLR2 in NTHi WCL induced beta-defensin 2 expression was also confirmed in vivo. The induction of mouse beta-defensin 2 (mBD-2) mRNA by NTHi WCL in TLR2 KO mice middle ear was much lower than that of an age matched wild type control.
###end p 62
###begin p 63
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 409 411 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 412 414 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 415 417 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 584 586 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 587 589 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 819 821 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 822 824 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1098 1100 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1101 1103 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1239 1241 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1242 1244 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1487 1489 1445 1447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1490 1492 1448 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1493 1495 1451 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 532 536 <span type="species:ncbi:727">NTHi</span>
###xml 799 803 <span type="species:ncbi:727">NTHi</span>
###xml 863 867 <span type="species:ncbi:727">NTHi</span>
###xml 897 901 <span type="species:ncbi:727">NTHi</span>
###xml 1277 1281 <span type="species:ncbi:727">NTHi</span>
Beta-defensin exhibits not only innate immune activity such as direct killing of invading bacteria but also has been known to mediate adaptive immunity [60]. The secreted beta-defensin functions as an chemoattractant for CCR6 positive immature dendritic and memory T cells, facilitating the transition from innate immunity to adaptive immunity by producing inflammatory cytokines and chemokines such as IL-1 [19,60-62]. Our previous studies showed that IL-1alpha is a potent inducer of beta-defensin 2 and acts synergistically with NTHi WCL to up-regulate beta-defensin 2 expression [27,30]. These experiments showed that IL-1alpha-induced beta-defensin 2 expression was mediated through the Src-dependent Raf-MEK1/2-ERK MAPK pathway and uses the same TIR domain of TLR2 that recognizes the unknown NTHi WCL component [27,34]. The synergism between IL-1alpha and NTHi may be explained as follows: NTHi WCL stimulates HMEEC-1 through MyD88 dependent TLR2 signaling pathway inducing an early phase response with subsequent beta-defensin 2 and proinflammatory cytokine (such as IL-1alpha) production [13,34]. The secreted IL-1alpha may further stimulate the cells through MyD88 independent IL-1R pathway that initiates a late phase response [13,34]. Therefore, even though active NTHi component/ligand and IL-1alpha utilize the same TIR domain and are working through the p38 and ERK MAPK signaling pathways respectively, they can act synergistically to amplify beta-defensin 2 expression [13,34,63].
###end p 63
###begin p 64
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 741 743 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 744 746 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 549 553 <span type="species:ncbi:727">NTHi</span>
###xml 610 614 <span type="species:ncbi:727">NTHi</span>
###xml 689 693 <span type="species:ncbi:727">NTHi</span>
Recently a new group of receptors, Nacht-LRR, NOD-like Receptor, or CATERPILLAR (NLR), has been reported that resemble and function as intracellular receptors for bacterial recognition [19,64,65]. These receptors not only recognize invasive microbes and appropriate bacterial components/ligands, but also play pivotal roles in triggering inflammatory response by converting the inactive forms of pro-cytokines to active mature cytokines [66,67]. Based on these facts, we speculate that these intracellular receptors may contribute to increasing the NTHi induced beta-defensin 2 expression in HMEEC-1. Although NTHi is considered as a mucosal surface pathogen, there have been reports that NTHi can be internalized in the mucosal epithelium [68,69]. While the significance of this bacterial internalization in the pathogenesis of otitis media is not yet known, it is possible that such internalized bacterial components can also induce beta-defensin up-regulation. Studies are currently underway in our laboratory to test this possibility.
###end p 64
###begin title 65
Conclusion
###end title 65
###begin p 66
###xml 37 41 <span type="species:ncbi:727">NTHi</span>
###xml 162 166 <span type="species:ncbi:727">NTHi</span>
In conclusion, we have observed that NTHi WCL signals through a TLR2 dependent TIR domain similar to IL-1alpha. However, this is where the similarities end: Both NTHi WCL and IL-1alpha signal through entirely different sets of downstream players, possibly leading to a synergistic induction of HBD-2 in infection.
###end p 66
###begin title 67
Competing interests
###end title 67
###begin p 68
The authors declare that they have no competing interests.
###end p 68
###begin title 69
Authors' contributions
###end title 69
###begin p 70
###xml 327 331 <span type="species:ncbi:727">NTHi</span>
###xml 543 548 <span type="species:ncbi:10090">mouse</span>
H-YL performed most of experiments and data analysis. TT performed the cell culture and DN transfection study. JS performed the siRNA study. AA performed the antibody blocking and Q-PCR analysis. J-IW participated in the siRNA study and helped Q-PCR. HP performed the western blot and ELISA studies. SKM prepared the lysate of NTHi, and assisted experiments related with siRNA. AA participated in study design and data analysis. RKP extracted RNA and performed Q-PCR study. S-HK participated in cell culture and Q-PCR analysis. S-SK collected mouse middle ear specimens and helped with Q-PCR. RG participated in data analysis and helped to draft the manuscript. DJL is recipient of NIDCD R01 DC05025-04, which supported this work and the studies were conducted in his laboratory, with him as the principal investigator. All authors read and approved the final version of the manuscript.
###end p 70
###begin title 71
Pre-publication history
###end title 71
###begin p 72
The pre-publication history for this paper can be accessed here:
###end p 72
###begin p 73

###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
This work was supported in part by grants from the NIH/NIDCD R01 grant (R01 DC05025-04) and P-30 grant (P30DC006276) to DJL.
###end p 75
###begin article-title 76
TCR gamma delta cells: a specialized T-cell subset in the immune system
###end article-title 76
###begin article-title 77
Acute otitis media
###end article-title 77
###begin article-title 78
###xml 52 74 52 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 52 74 <span type="species:ncbi:727">Haemophilus influenzae</span>
Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase
###end article-title 78
###begin article-title 79
Treatment of acute otitis media - challenges in the era of antibiotic resistance
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human beta-defensin-1 mRNA is transcribed in tympanic membrane and adjacent auditory canal epithelium
###end article-title 80
###begin article-title 81
Functional morphology of the mucosa of the middle ear and Eustachian tube
###end article-title 81
###begin article-title 82
Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review
###end article-title 82
###begin article-title 83
Middle ear fluid lysozyme source in experimental pneumococcal otitis media
###end article-title 83
###begin article-title 84
###xml 37 43 <span type="species:ncbi:10090">murine</span>
Development of secretory elements in murine tubotympanum: lysozyme and lactoferrin immunohistochemistry
###end article-title 84
###begin article-title 85
Lactoferrin in middle ear effusion
###end article-title 85
###begin article-title 86
###xml 99 121 99 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 99 121 <span type="species:ncbi:727">Haemophilus influenzae</span>
Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2
###end article-title 86
###begin article-title 87
TLR signaling pathways
###end article-title 87
###begin article-title 88
###xml 58 82 58 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Streptococcus pneumoniae</italic>
###xml 84 105 84 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella catarrhalis</italic>
###xml 122 144 122 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 58 82 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
###xml 84 105 <span type="species:ncbi:480">Moraxella catarrhalis</span>
###xml 122 144 <span type="species:ncbi:727">Haemophilus influenzae</span>
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae
###end article-title 88
###begin article-title 89
Four reasons to consider a novel class of innate immune molecules in the oral epithelium
###end article-title 89
###begin article-title 90
Defensins
###end article-title 90
###begin article-title 91
Antimicrobial peptides of vertebrates
###end article-title 91
###begin article-title 92
Mammalian defensins in the antimicrobial immune response
###end article-title 92
###begin article-title 93
Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways
###end article-title 93
###begin article-title 94
Innate immune response of oral and foreskin keratinocytes: utilization of different signaling pathways by various bacterial species
###end article-title 94
###begin article-title 95
Current status of defensins and their role in innate and adaptive immunity
###end article-title 95
###begin article-title 96
[beta]-defensins in lung host defense
###end article-title 96
###begin article-title 97
Antimicrobial polypeptides
###end article-title 97
###begin article-title 98
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 160 167 <span type="species:ncbi:8355">Xenopus</span>
Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction
###end article-title 98
###begin article-title 99
Discovery of five conserved beta -defensin gene clusters using a computational search strategy
###end article-title 99
###begin article-title 100
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Significance of human beta-defensins in the epithelial lining fluid of patients with chronic lower respiratory tract infections
###end article-title 100
###begin article-title 101
###xml 132 137 <span type="species:ncbi:9606">human</span>
Activation of a Src-dependent Raf-MEK1/2-ERK signaling pathway is required for IL-1alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation
###end article-title 102
###begin article-title 103
By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide
###end article-title 103
###begin article-title 104
###xml 57 79 57 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 57 79 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Synergistic effect of interleukin 1 alpha on nontypeable Haemophilus influenzae-induced up-regulation of human beta-defensin 2 in middle ear epithelial cells
###end article-title 104
###begin article-title 105
###xml 25 35 25 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 25 35 <span type="species:ncbi:7227">Drosophila</span>
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity
###end article-title 105
###begin article-title 106
Toll-like receptors: function and roles in lung disease
###end article-title 106
###begin article-title 107
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense
###end article-title 107
###begin article-title 108
Toll-like receptor signalling
###end article-title 108
###begin article-title 109
Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily
###end article-title 109
###begin article-title 110
###xml 71 93 71 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 71 93 <span type="species:ncbi:727">Haemophilus influenzae</span>
Localization of high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae by immunoelectron microscopy
###end article-title 110
###begin article-title 111
###xml 64 86 64 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 64 86 <span type="species:ncbi:727">Haemophilus influenzae</span>
Evolutionary and functional relationships among the nontypeable Haemophilus influenzae HMW family of adhesins
###end article-title 111
###begin article-title 112
###xml 12 34 12 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 12 34 <span type="species:ncbi:727">Haemophilus influenzae</span>
Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans
###end article-title 112
###begin article-title 113
###xml 107 129 107 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 107 129 <span type="species:ncbi:727">Haemophilus influenzae</span>
Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins
###end article-title 113
###begin article-title 114
###xml 141 163 141 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 141 163 <span type="species:ncbi:727">Haemophilus influenzae</span>
Identification of the ADP-L-glycero-D-manno-heptose-6-epimerase (rfaD) and heptosyltransferase II (rfaF) biosynthesis genes from nontypeable Haemophilus influenzae 2019
###end article-title 114
###begin article-title 115
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 115 143 <span type="species:ncbi:333760">human papillomavirus type 16</span>
Immortalization of normal adult human middle ear epithelial cells using a retrovirus containing the E6/E7 genes of human papillomavirus type 16
###end article-title 115
###begin article-title 116
###xml 44 49 <span type="species:ncbi:9606">human</span>
Cytokine regulation of mucin secretion in a human middle ear epithelial model
###end article-title 116
###begin article-title 117
###xml 88 110 88 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 88 110 <span type="species:ncbi:727">Haemophilus influenzae</span>
Transforming growth factor-beta-Smad signaling pathway negatively regulates nontypeable Haemophilus influenzae-induced MUC5AC mucin transcription via mitogen-activated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK
###end article-title 117
###begin article-title 118
The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7
###end article-title 118
###begin article-title 119
Immunobarriers of the tubotympanum
###end article-title 119
###begin article-title 120
Analysis of immunocompetent cells in the middle ear mucosa
###end article-title 120
###begin article-title 121
###xml 39 49 <span type="species:ncbi:10141">guinea pig</span>
The development of mucosal immunity in guinea pig middle ears
###end article-title 121
###begin article-title 122
###xml 45 67 45 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 45 67 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 162 172 <span type="species:ncbi:10152">chinchilla</span>
Evaluation of phase variation of nontypeable Haemophilus influenzae lipooligosaccharide during nasopharyngeal colonization and development of otitis media in the chinchilla model
###end article-title 122
###begin article-title 123
###xml 30 52 30 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 30 52 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 56 61 <span type="species:ncbi:9606">human</span>
Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation
###end article-title 123
###begin article-title 124
###xml 78 100 78 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 78 100 <span type="species:ncbi:727">Haemophilus influenzae</span>
Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae
###end article-title 124
###begin article-title 125
###xml 42 64 42 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 42 64 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway
###end article-title 125
###begin article-title 126
###xml 107 129 107 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 107 129 <span type="species:ncbi:727">Haemophilus influenzae</span>
Detection and characterization of pediatric serum antibody to the OMP P5-homologous adhesin of nontypeable Haemophilus influenzae during acute otitis media
###end article-title 126
###begin article-title 127
###xml 25 47 25 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 25 47 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 49 53 <span type="species:ncbi:727">NTHi</span>
Developing a nontypeable Haemophilus influenzae (NTHi) vaccine
###end article-title 127
###begin article-title 128
###xml 70 92 70 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 70 92 <span type="species:ncbi:727">Haemophilus influenzae</span>
Distribution of bacterial proteins in biofilms formed by non-typeable Haemophilus influenzae
###end article-title 128
###begin article-title 129
###xml 83 105 83 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 83 105 <span type="species:ncbi:727">Haemophilus influenzae</span>
Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains
###end article-title 129
###begin article-title 130
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice
###end article-title 130
###begin article-title 131
###xml 115 137 115 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">haemophilus influenzae</italic>
###xml 115 137 <span type="species:ncbi:727">haemophilus influenzae</span>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung
###end article-title 131
###begin article-title 132
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family
###end article-title 132
###begin article-title 133
###xml 63 68 <span type="species:ncbi:9606">human</span>
Toll-like receptor 2-mediated expression of beta-defensin-2 in human corneal epithelial cells
###end article-title 133
###begin article-title 134
Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense
###end article-title 134
###begin article-title 135
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
The structure of human macrophage inflammatory protein-3alpha /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins
###end article-title 135
###begin article-title 136
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2
###end article-title 136
###begin article-title 137
###xml 23 33 23 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 23 33 <span type="species:ncbi:7227">Drosophila</span>
The immune response of Drosophila
###end article-title 137
###begin article-title 138
Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors
###end article-title 138
###begin article-title 139
Intracellular pattern recognition receptors in the host response
###end article-title 139
###begin article-title 140
Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation
###end article-title 140
###begin article-title 141
The inflammasome: first line of the immune response to cell stress
###end article-title 141
###begin article-title 142
###xml 80 102 80 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 80 102 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 108 113 <span type="species:ncbi:9606">human</span>
The importance of a beta-glucan receptor in the nonopsonic entry of nontypeable Haemophilus influenzae into human monocytic and epithelial cells
###end article-title 142
###begin article-title 143
###xml 53 75 53 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae</italic>
###xml 53 75 <span type="species:ncbi:727">Haemophilus influenzae</span>
Identification and characterization of a nontypeable Haemophilus influenzae putative toxin-antitoxin locus
###end article-title 143

